Arkolith/Insider Trading/VIR/Form 4

Eisner Mark

EVP and Chief Medical OfficerVir Biotechnology, Inc. (VIR) · full profile →Form 4 · filed Jul 17, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$57K
Net Open-Market Flow
-$57K
Transactions
2
2 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jul 17, 2025Sell(S)4K$5.47$20K105K
Jul 15, 2025Sell(S)7K$5.47$37K108K

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001628280-25-035269) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML